Log In
BCIQ
Print this Print this
 

Catioprost (Nova21027)

  Manage Alerts
Collapse Summary General Information
Company Santen Pharmaceutical Co. Ltd.
DescriptionOcular formulation of latanoprost using Novasorb cationic emulsion technology
Molecular Target Prostaglandin F2 alpha receptor (PGF2 alpha)
Mechanism of ActionProstaglandin F (FP) receptor agonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$134.2M

$134.2M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/02/2012

$134.2M

$134.2M

0

Get a free BioCentury trial today